Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Eli Lilly Jaypirca to lead BTK inhibitor market for leukemia (NYSE:LLY) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.